The role of disodium pamidronate in the management of bone pain due to malignancy

Abstract

A number of controlled studies have recently demonstrated the role of disodium pamidronate in the prevention of skeletal complications in patients with metastatic bone disease due to breast cancer and multiple myeloma. They have also shown that it relieves pain and is well tolerated.

The aim of this open prospective study was to evaluate the acceptability of a new schedule of pamidronate infusion and to assess pain, analgesic consumption and the Karnofsky Performance Status (KPS) in patients with metastatic bone pain treated with pamidronate in association or not with chemotherapy, radiotherapy, and hormone therapy. Patients with different types of cancer and at least one painful bone metastasis were treated with two cycles of 60 mg intravenous (iv) pamidronate weekly for three consecutive doses, with a 3-week interval between the two cycles (six infusions over 7 weeks), followed by one infusion every 3 weeks for a total of 24 infusions. Two hundred patients were enrolled in the study, of whom 94 received at least the first six infusions; 25 patients received all 24 infusions.

Pamidronate was well tolerated in the majority of the patients both during the first six infusions and during the whole study period.

In the patients under study, pain intensity decreased compared with T₀sub after the first two infusions (second week of treatment). The mean equivalent daily dose of oral morphine required ranged from 21.5 to 41.5 mg/day and was low and stable during the study. For the patients who remained in the study, the KPS remained around 70 during the whole treatment period and intrasubject analysis showed a substantial stability of the KPS within each subject.

A first fracture occurred within 321 days in 25% of the whole population under study.

Pamidronate represents a further valid therapy to add to an already consolidated list of therapies such as radiotherapy, chemotherapy, hormone therapy and orthopaedic intervention in the pain management of patients with bone metastases. Future studies are necessary to evaluate the role of pamidronate and the appropriate schedule in patients with advanced or terminal cancer who are no longer being treated with oncological therapies.

Keywords

advanced cancer patients bone metastases pain disodium pamidronate palliative treatment

Get full access to this article

View all access options for this article.

References

Twycross RG , Fairfield S . Pain in far-advanced cancer. Pain 1982; 14: 303–310.

Body JJ . Metastatic bone disease: clinical and therapeutical aspects. Bone 1992; 13: 557–562.

Hillner BE , Ingle JN , Berenson JR et al. American Society of Clinical Oncology guideline on the role of bisphosphonates in breast cancer. J Clin Oncol 2000; 18: 1378–1391.

Mercadante S . Malignant bone pain: pathophysiology and treatment. Pain 1997; 69: 1–18.

Ripamonti C , Fulfaro F . Malignant bone pain: pathophysiology and treatments. Curr Rev Pain 2000; 4: 187–196.

Berenson J , Lichtenstein A , Porter L et al. Efficacy of pamidronate in reducing skeletal events in patients with advanced multiple myeloma. N Engl J Med 1996; 334: 488–493.

Koeberle D , Bacchus L , Thuerlimann B , Senn HJ . Pamidronate treatment in patients with malignant osteolytic bone disease and pain: a prospective randomized double-blind trial. Support Care Cancer 1999; 7: 21–27.

Theriault RL , Lipton A , Hortobagyi GN et al. Pamidronate reduces skeletal morbidity in women with advanced breast cancer and lytic bone lesions: a randomized, placebo-controlled trial. J Clin Oncol 1999; 17: 846–854.

Glover D , Lipton A , Keller A et al. Intravenous pamidronate disodium treatment of bone metastases in patients with breast cancer. A dose-seeking study. Cancer 1994; 74: 2949–2955.

10.

Diel IJ , Solomayer EF , Costa SD et al. Reduction in new metastases in breast cancer with adjuvant clodronate treatment. N Engl J Med 1998; 339: 357–363.

11.

Coleman RE , Purohit OP , Vinholes JJ et al. High dose pamidronate: clinical and biochemical effects in metastatic bone disease. Cancer 1997; 80: 1686–1690.

12.

Berenson JR , Lichtenstein A , Porter L et al. Long-term pamidronate treatment of advanced multiple myeloma patients reduces skeletal events. J Clin Oncol 1998; 16: 593–602.

13.

Conte PF , Latreille J , Mauriac L et al. Delay in progression of bone metastases in breast cancer patients treated with intravenous pamidronate: results from a multinational randomized, controlled trial. J Clin Oncol 1996; 14: 2552–2559.

14.

Hortobagyi GN , Theriault RL , Lipton A et al. Long-term prevention of skeletal complications of metastatic breast cancer with pamidronate. J Clin Oncol 1998; 16: 2038–2044.

15.

Lipton A , Hershey PA , Theriault R et al. Long-term reduction of skeletal complications in breast cancer patients with osteolytic bone metastases receiving hormone therapy, by monthly 90 mg pamidronate infusions [abstract]. Proc Am Soc Clin Oncol 1997; 16: 152–153.

16.

Fleisch H . Bisphosphonates–mechanisms of action. In: Burckhardt P ed. Disodium pamidronate (APD) in the treatment of malignancy-related disorders. Toronto: Hans-Huber, 1988: 21–35.

17.

Fulfaro F , Casuccio A , Ticozzi C , Ripamonti C . The role of bisphosphonates in the treatment of painful metastatic bone disease: a review of phase III trials. Pain 1998; 78: 157–169.

18.

Hortobagyi GN , Theriault RL , Porter L et al. Efficacy of pamidronate in reducing skeletal complications in patients with breast cancer and lytic bone metastases. N Engl J Med 1996; 335: 1785–1791.

19.

Erem T , Koc M , Polat P et al. The comparison of radiotherapy and radiotherapy plus pamidronate on pain palliation of metastatic bone disease, abstract 1489. ECCO, Vienna, 12–16 September 1999: 5366.

20.

Bloomfield DJ . Should bisphosphonates be part of the standard therapy of patients with multiple myeloma or bone metastases from other cancers? An evidence-based review. J Clin Oncol 1998; 16: 1218–1225.

21.

Krempien B , Wingen F , Eichmann T et al. Protective effects of a prophylactic treatment with the bisphosphonate 3-amino-1-hydroxypropane-1,1-bisphosphonic acid on the development of tumour osteopathies in the rat: experimental studies with the Walker carcinosarcoma 256. Oncology 1988; 45: 41–46.

22.

van der Pluijm G , Vloedgraven H , van Beek E et al. Bisphosphonates inhibit the adhesion of breast cancer cells to bone matrices in vitro. J Clin Invest 1996; 98: 698–705.

23.

Boissier S , Magnetto S , Frappart L et al. Bisphosphonates inhibit prostate and breast cancer carcinoma cell adhesion to unmineralized and mineralized bone extracellular matrices. Cancer Res 1997; 57: 3890–3894.

24.

Shipman CM , Rogers MJ , Apperley JF , Russell RG , Croucher PI . Bisphosphonates induce apoptosis in human myeloma cell lines: a novel anti-tumour activity. Br J Haematol 1997; 98: 665–672.

25.

Gessner U , Koeberle D , Thuerlimann B , Bacchus L , Horisberger B . Economic analysis of terminal care for patients with malignant osteolytic bone disease and pain treated with pamidronate. Support Care Cancer 2000; 8: 115–122.

26.

Berenson JR , Lipton A . Pharmacology and clinical efficacy of bisphosphonates. Curr Opin Oncol 1998; 10: 566–571.

27.

Ghose K , Waterworth R , Trolove P et al. Uveitis associated with pamidronate. Aust NZ J Med 1994; 24: 320.

28.

Macarol V , Fraunfelder FT . Pamidronate disodium and possible ocular adverse drug reactions. Am J Ophthalmol 1994; 118: 220–224.

29.

Coleman RE , Rubens RD . The clinical course of bone metastases from breast cancer. Br J Cancer 1987; 55: 61–66.

30.

Cascinu S , Graziano F , Alessandroni P et al. Different doses of pamidronate in patients with painful osteolytic bone metastases. Support Care Cancer 1998; 6: 139–143.

31.

Body JJ , Bartl R , Burckhardt P et al. Current use of bisphosphonates in oncology. JCO 1998; 16: 3890–3899.

32.

Body JJ . Bisphosphonates for metastatic bone pain. Support Care Cancer 1999; 7: 1–3.